Start here if you're new
what it is
Genelux is building virus-based cancer treatments for hard-to-treat solid tumors.
how it gets paid
Last year Genelux made $8K in revenue. Olvi-Vec collaboration was the main engine at $3K, or 38% of sales.
what just happened
Genelux posted $8K in revenue and -$0.62 EPS.
At a glance
B balance sheet — gets the job done, barely
-$0.95 fy2024 eps est
$0M fy2024 rev est
n/a operating margin
1.8 beta
xvary composite: 47/100 — below average
What they do
Genelux is building virus-based cancer treatments for hard-to-treat solid tumors.
Olvi-Vec is a modified vaccinia virus. Virus → cancer-killing delivery vehicle → the idea is to make tumors do the heavy lifting. You are looking at $8K of annual revenue versus a $116M market cap, so the stock pays for clinical hope, not sales. CHOICE is the lab engine (discovery platform → finds new candidates → so what: it keeps the pipeline from being a one-drug story).
How they make money
$8K
annual revenue
Olvi-Vec collaboration
$3K
CHOICE platform work
$3K
Newsoara license revenue
$1K
Other revenue
$1K
The products that matter
phase 3 clinical asset
olvi-vec
$8K revenue base · $116M valuation
it is the only clinical-stage program tied to this story. with just $8,000 of annual revenue and a $116M market cap, your equity value is effectively attached to one asset.
pipeline
Key numbers
$8K
annual revenue
That is the whole top line. It is smaller than one decent marketing spend.
$116M
market cap
That is what the market pays for the science before sales show up.
$20M
offering size
Fresh cash came from stock sales, which dilutes your slice.
$1M
long-term debt
Debt is tiny at 1% of capital, so the pain comes from dilution, not leverage.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $1M (1% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for GNLX right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Genelux posted $8K in revenue and -$0.62 EPS.
Revenue was flat vs. prior year, and gross margin was 0.0%. That is a lab, not a sales engine.
$8K
revenue
-$0.62
eps
0.0%
gross margin
revenue
The $8K revenue line matters because it says the company is still pre-commercial.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is olvi-vec pivotal trial failure. this is a one-asset biotech with $8,000 of revenue, so clinical disappointment would hit the entire story at once.
med
olvi-vec trial failure
the company does not have another operating engine to fall back on. if the pivotal readout is weak, the $116M valuation loses its main support.
impact: this puts the core equity thesis at risk because one asset currently carries essentially all of the future value.
med
dilution before value creation
the page already references a $20M offering and 23% exposure to financial distress. that tells you financing risk is not theoretical.
impact: more equity issuance can pressure existing holders before the company proves the program is worth materially more.
med
thin trading and violent price moves
a $116M market cap, 1.8 beta, and 5 / 100 price stability is the setup for sharp moves on limited liquidity.
impact: even if your thesis is right, the path can still be ugly enough to shake you out first.
between the one-asset pipeline, $8,000 revenue base, and recent $20M financing, this stock is priced more on future clinical credibility than on present business fundamentals.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
final olvi-vec trial data
the investment case is waiting on decisive clinical evidence. that matters more than routine quarterly noise.
financing
what the $20M offering actually buys
if the raise funds the next real readout, dilution may buy time. if it only buys more waiting, you are funding drift.
volatility
beta at 1.8 and price stability at 5 / 100
those two numbers say the stock can move faster than your comfort level, especially around headlines.
business quality
whether revenue stays basically zero
$8,000 of annual revenue is a reminder that this remains a science project in market form, not a scaled commercial company.
Analyst rankings
coverage
limited
in human-speak, there is not enough broad coverage here to treat consensus like a sturdy signal.
forecast quality
thin
with $0M expected revenue and one core asset, forecasts hinge more on binary trial outcomes than on normal operating trends.
source: institutional data
Institutional activity
institutional ownership data for GNLX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive